Ferric Derisomaltose is Used for treating iron deficiency anemia in adult patients with intolerance to oral iron or unsatisfactory response to oral iron, and non-hemodialysis dependent chronic kidney disease, by administering ferric derisomaltose. It was first introduced by Pharmacosmos As in its drug Monoferric on Jan 16, 2020.

Ferric Derisomaltose Patents

Given below is the list of patents protecting Ferric Derisomaltose, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Monoferric	US11633489	Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant	Jun 22, 2036	Pharmacosmos
Monoferric	US8815301	Stable iron oligosaccharide compound	Aug 14, 2029	Pharmacosmos
Monoferric	US10414831	Stable iron oligosaccharide compound	Mar 25, 2029	Pharmacosmos
Monoferric	US11851504	Stable iron oligosaccharide compound	Mar 25, 2029	Pharmacosmos
Monoferric	US12030962	Stable iron oligosaccharide compound	Mar 25, 2029	Pharmacosmos

Add above patents to watchlist

Ferric Derisomaltose's Family Patents

Full family tree